Neumora Therapeutics, Inc. (NMRA)
After hours:
| Previous Close | 9.31 |
| Open | 9.30 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 8.95 - 9.38 |
| 52 Week Range | 8.82 - 21.00 |
| Volume | |
| Avg. Volume | 644,777 |
| Market Cap | 1.463B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.59 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.25 |
Simply Wall St.This Neumora Therapeutics Insider Increased Their Holding In The Last Year
Insiders were net buyers of Neumora Therapeutics, Inc.'s ( NASDAQ:NMRA ) stock during the past year. That is, insiders...
GlobeNewswireNeumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to improve these symptoms in MDD in a Phase 2 study Navacaprant is also currently in Phase 3 development for the treatment of MDD with data from KOASTAL-1 anticipated in the fourth quarter of 2024 WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pip
- GlobeNewswire
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
On-track to report topline Phase 3 data from KOASTAL-1 study with navacaprant in MDD; guidance narrowed to fourth quarter of 2024 Multiple clinical study initiations planned in second quarter of 2024, including Phase 2 study in bipolar depression with navacaprant and Phase 1b study in Alzheimer's disease agitation with NMRA-511 Strong financial position with $423.0 million in cash, cash equivalents and marketable securities expected to support operations into 2026, providing runway through multi
